Werbung
Werbung

QNCX

QNCX logo

Quince Therapeutics, Inc. Common Stock

2.69
USD
Gesponsert
+0.01
+0.56%
09. Jan., 15:57 UTC -5
Geschlossen
exchange

Nach-Markt

2.77

+0.07
+2.60%

QNCX Ergebnisberichte

Positives Überraschungsverhältnis

QNCX übertreffen die 9 der letzten 20Schätzungen.

45%

Nächster Bericht

Datum des nächsten Berichts
23. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.19
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
-24.00%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-32.14%

Quince Therapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, QNCX reported earnings of -0.25 USD per share (EPS) for Q3 25, missing the estimate of -0.22 USD, resulting in a -13.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.75% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an decrease of -24.00% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Quince Therapeutics, Inc. Common Stock reported EPS of -$0.25, missing estimates by -13.28%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.75%, changed from $1.71 before the earnings release to $1.68 the day after.
The next earning report is scheduled for 23. März 2026.
Based on 8 analysts, Quince Therapeutics, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung